Research programme: rod-derived cone viability factor therapeutics - Fovea Pharmaceuticals

Drug Profile

Research programme: rod-derived cone viability factor therapeutics - Fovea Pharmaceuticals

Alternative Names: FOV 2501

Latest Information Update: 03 Feb 2011

Price : $50

At a glance

  • Originator INSERM; Novartis
  • Developer Fovea Pharmaceuticals
  • Class Proteins
  • Mechanism of Action TXNL6 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • Available For Licensing Yes - Eye disorders

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 14 Jul 2010 Recombinant human rod-derived cone viability factor is available for licensing worldwide (http://www.fovea-pharma.com)
  • 14 Jul 2010 Preclinical development is ongoing in France
  • 07 Jan 2008 FOV 2501 received Orphan Drug status for Retinal disorders in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top